PIK3CA R88Q

CI-VAR-00003926Explore in graph →NP_006209.2:p.Arg88GlnNM_006218.4:c.263G>AClinVar 376049 CIViC 929 rs121913287

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
PIK3CA R88Q OR PIK3CA C420R OR PIK3CA M1043V OR PIK3CA M1043I OR PIK3CA M1043T	Fulvestrant + Inavolisib + PalbociclibCombination	Predictive	A	Supports Sensitivity Response	3	accepted	EID12539 The phase III INAVO120 trial (NCT04191499) in 325 patients with endocrine-resistant, PIK3CA-mutated HR⁺/HER2⁻ locally advanced or metastatic breast cancer evaluated inavolisib plus palbociclib and ful… (full text at CIViC) PMID 40845250 · Wedam et al., 2025 · Open in CIViC	civic
Malignant Colorectal Neoplasm1
PIK3CA R88Q	Cetuximab + IrinotecanCombination	Predictive	C	Does Not Support Resistance	3	accepted

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376049	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Ovarian neoplasm; Cowden syndrome; PIK3CA related overgrowth syndrome; Abnormal cerebral morphology; Megalencephaly-capillary malformation-polymicrogyria syndrome; Cowden syndrome 5; Neoplasm; CLOVES syndrome; Pilocytic astrocytoma; Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype; Medulloblastoma WNT activated; Giant cell glioblastoma; PIK3CA-related disorder

HER2 Negative Breast Cancer1unmapped disease
PIK3CA R88Q	Capivasertib + FulvestrantCombination	Predictive	A	Supports Sensitivity Response	2	accepted	EID12034 In this phase 3 double-blind trial, the efficacy of capivasertib and fulvestrant combination therapy was tested in 708 patients with HR+/HER2- breast cancer. Among these 708 patients, 40.8% (n = 289) … (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC	civic